Caribou Biosciences (CRBU) Price & Analysis

Compare

788 Followers

CRBU Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $3.00

Previous CloseN/A

Volume598.80K

Average Volume (3M)810.19K

Market Cap

$170.42M

Enterprise Value-$40.88M

Total Cash (Recent Filing)$208.47M

Total Debt (Recent Filing)$26.22M

Price to Earnings (P/E)―

Beta2.64

Next Earnings

Nov 11, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding93,123,240

10 Day Avg. Volume478,587

30 Day Avg. Volume810,188

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.24

Enterprise Value/Revenue-4.12

Enterprise Value/Gross Profit-5.19

Enterprise Value/Ebitda0.25

Forecast

1Y Price Target

$4.75

Price Target Upside163.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial PositionCRBU ended the period with $183.9mm in cash and equivalents, expected to fund future developments.

Strategic FocusCaribou announced a strategic reprioritization to focus on oncology programs for CB-010 in large B cell lymphoma (LBCL) and CB-011 in multiple myeloma (MM) with a workforce (~32%) and cost reduction.

ValuationAnalyst continues to consider Caribou undervalued and believes that the company's current situation involves a much more favorable position from which to weather equity capital markets volatility.

Bears Say

Pipeline RisksRisks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and failure to achieve favorable clinical results with other pipeline candidates.

Price Target ReductionReducing the price target from $10 to $3.

Program DiscontinuationThe discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research does reduce the value from the pipeline.

Caribou Biosciences News

Caribou Biosciences: Promising Clinical Progress and Strong Financial Position Justify Buy Rating

Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Caribou Biosciences on August 13 and set a...

1M ago

CRBU

Caribou Biosciences Reports Increased Losses Amid R&D Efforts

Caribou Biosciences, Inc. ( ($CRBU) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

CRBU

Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

Reports Q2 revenue $2.7M, consensus $1.64M. The company had $183.9M in cash, cash equivalents, and marketable securities as...

1M ago

CRBU

Caribou Biosciences, Inc. (CRBU) Q2 Earnings Cheat Sheet

Caribou Biosciences, Inc. (CRBU) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street...

1M ago

CRBU

Caribou Biosciences Regains Nasdaq Compliance

Caribou Biosciences ( ($CRBU) ) just unveiled an update. On June 18, 2025, Caribou Biosciences announced that it...

3M ago

CRBU

Caribou Biosciences Confirms Director Elections and Auditor

The latest announcement is out from Caribou Biosciences ( ($CRBU) ). On June 12, 2025, Caribou Biosciences, Inc....

3M ago

CRBU

Caribou Biosciences Reports Q1 2025 Financial Results

Caribou Biosciences, Inc. ( ($CRBU) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

CRBU

Caribou Biosciences: Strong Pipeline and Financial Position Justify Buy Rating

Caribou Biosciences (CRBU – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

4M ago

CRBU

Is CRBU a Buy, Before Earnings?

Caribou Biosciences, Inc. (CRBU) is scheduled to report 1st quarter earnings on 05/13/2025. Regarding Q1 estimates, Wall Street...

4M ago

CRBU

Caribou Biosciences files $300M mixed securities shelf

17:04 EDT Caribou Biosciences (CRBU) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

CRBU

Caribou Biosciences price target lowered to $9 from $11 at BofA

BofA lowered the firm’s price target on Caribou Biosciences (CRBU) to $9 from $11 and keeps a Buy...

5M ago

CRBU

Strategic Refocus and Upcoming Catalysts Support Buy Rating for Caribou Biosciences

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report), reducing...

5M ago

CRBU

Caribou Biosciences price target lowered to $3 from $9 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Caribou Biosciences (CRBU) to $3 from $9...

5M ago

CRBU

Strategic Restructuring and Focus on Oncology Drive Buy Rating for Caribou Biosciences

Caribou Biosciences (CRBU – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

5M ago

CRBU

CRBU FAQ

What was Caribou Biosciences’s price range in the past 12 months?

Caribou Biosciences lowest stock price was $0.66 and its highest was $3.00 in the past 12 months.

What is Caribou Biosciences’s market cap?

Caribou Biosciences’s market cap is $170.42M.

When is Caribou Biosciences’s upcoming earnings report date?

Caribou Biosciences’s upcoming earnings report date is Nov 11, 2025 which is in 53 days.

How were Caribou Biosciences’s earnings last quarter?

Caribou Biosciences released its earnings results on Aug 12, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.052.

Is Caribou Biosciences overvalued?

According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Caribou Biosciences pay dividends?

Caribou Biosciences does not currently pay dividends.

What is Caribou Biosciences’s EPS estimate?

Caribou Biosciences’s EPS estimate is -0.35.

How many shares outstanding does Caribou Biosciences have?

Caribou Biosciences has 93,123,240 shares outstanding.

What happened to Caribou Biosciences’s price movement after its last earnings report?

Caribou Biosciences reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went up 8.939%.

Which hedge fund is a major shareholder of Caribou Biosciences?

Currently, no hedge funds are holding shares in CRBU

Caribou Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-68.93%

Trailing 12-Months

Asset Growth

-40.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Caribou Biosciences

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

Caribou Biosciences (CRBU) Earnings & Revenues

Historic Earnings Reports

CRBU Stock 12 Month Forecast

Average Price Target

$4.75

▲(163.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.5046153846153847,3.1292307692307695,3.753846153846154,4.378461538461538,5.003076923076923,5.627692307692308,6.252307692307693,6.876923076923077,7.501538461538462,8.126153846153848,8.750769230769231,9.375384615384615,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.1007692307692305,2.3215384615384616,2.542307692307692,2.763076923076923,2.983846153846154,3.2046153846153844,3.4253846153846155,3.646153846153846,3.8669230769230767,4.087692307692308,4.308461538461538,4.529230769230769,{"y":4.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.8123076923076922,1.7446153846153845,1.6769230769230767,1.609230769230769,1.5415384615384613,1.4738461538461538,1.406153846153846,1.3384615384615384,1.2707692307692307,1.203076923076923,1.1353846153846154,1.0676923076923077,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.59,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >